Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics (NASDAQ: ELVN), sold 20,000 shares on January 20, 2026, generating proceeds amounting to $535,098, according to the company's Form 4 filing submitted to the Securities and Exchange Commission. These sales were executed under a pre-established 10b5-1 trading arrangement.
The divestiture involved shares indirectly held through The Lyssikatos Revocable Trust 12/15/2011, where Lyssikatos functions as trustee. The sales broke down into two tranches: initially, 5,491 shares were sold at prices ranging from $25.605 to $26.5928 per share, averaging $26.373; subsequently, 14,509 shares exchanged hands between $26.6137 and $27.344 per share, with an average sale price of $26.8995.
Following the transactions, Lyssikatos maintains indirect ownership of 745,188 Enliven Therapeutics shares.
Enliven Therapeutics, a clinical-stage oncology company specializing in treatments for chronic myeloid leukemia (CML), currently holds a market capitalization of approximately $1.61 billion. Despite reporting a diluted earnings per share of -$1.81 over the last twelve months, the company exhibits a strong financial position characterized by cash and liquid assets that exceed short-term liabilities. Its current ratio stands notably high at 32.95, reflecting solid liquidity.
Recently, Enliven reported encouraging Phase 1b clinical trial results for its CML drug candidate, ELVN-001. The study demonstrated a cumulative major molecular response (MMR) rate of 69% across various patient cohorts within 24 weeks, alongside 53% achieving MMR by this time frame. Notably, a deep molecular response was observed in 35% of patients within the randomized groups.
In parallel with clinical advancements, leadership changes have been implemented. Rick Fair was appointed Chief Executive Officer, succeeding co-founder Sam Kintz, who now leads the company’s pipeline strategy as Head of Pipeline. The organization also added Scott Garland to its Board of Directors as it prepares to initiate Phase 3 trials for ELVN-001.
However, competition is emerging in the CML treatment domain. At the American Society of Hematology Annual Meeting, Terns Pharmaceuticals presented promising data for their drug candidate, TERN-701, potentially intensifying the competitive landscape.
Meanwhile, Enliven continues its efforts to advance ELVN-001, underpinned by robust insider stock transactions and strategic leadership positioning, all amid a year that has seen its shares surge by 75.5%, with technical indicators suggesting the stock is currently in overbought territory.